VCAM1 and atherosclerosis: We intend to follow the localization of VCAM-1 targeted lipopolyplexes in the aortic valve and the therapeutic effect of V-LPP/shRunx2 in diabetes-induced changes in aortic heart valves in a murine model of atherosclerosis, developed previously [18].